Kim A Staats1, Timothy Wu1, Bing S Gan2, David B O'Gorman2, Roel A Ophoff3. 1. Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, CA, USA. 2. Department of Surgery, University of Western Ontario, St Joseph's Health Centre, London, Ontario, Canada; Cell and Molecular Biology Laboratory, Hand and Upper Limb Centre, London, Ontario, Canada. 3. Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, CA, USA; Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA, USA; Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, The Netherlands. Electronic address: Ophoff@ucla.edu.
Abstract
BACKGROUND: Dupuytren's Disease is a common disorder of the connective tissue characterized by progressive and irreversible fibroblastic proliferation affecting the palmar fascia. Progressive flexion deformity appears over several months or years and although usually painless, it can result in a serious handicap causing loss of manual dexterity. There is no cure for the disease and the etiology is largely unknown. A genome-wide association study of Dupuytren's Disease identified nine susceptibility loci with the strongest genetic signal located in an intron of EPDR1, the gene encoding the Ependymin Related 1 protein. OBJECTIVE: Here, we investigate the role of EPDR1 in Dupuytren's Disease. METHODS: We research the role of EPDR1 by assessing gene expression in patient tissue and by gene silencing in fibroblast-populated collagen lattice (FPCL) assay, which is used as an in vitro model of Dupuytren's contractures. RESULTS: The three alternative transcripts produced by the EPDR1 gene are all detected in affected Dupuytren's tissue and control unaffected palmar fascia tissue. Dupuytren's tissue also contracts more in the FPCL paradigm. Dicer-substrate RNA-mediated knockdown of EPDR1 results in moderate late stage attenuation of contraction rate in FPCL, implying a role in matrix contraction. CONCLUSION: Our results suggest functional involvement of EPDR1 in the etiology of Dupuytren's Disease.
BACKGROUND: Dupuytren's Disease is a common disorder of the connective tissue characterized by progressive and irreversible fibroblastic proliferation affecting the palmar fascia. Progressive flexion deformity appears over several months or years and although usually painless, it can result in a serious handicap causing loss of manual dexterity. There is no cure for the disease and the etiology is largely unknown. A genome-wide association study of Dupuytren's Disease identified nine susceptibility loci with the strongest genetic signal located in an intron of EPDR1, the gene encoding the Ependymin Related 1 protein. OBJECTIVE: Here, we investigate the role of EPDR1 in Dupuytren's Disease. METHODS: We research the role of EPDR1 by assessing gene expression in patient tissue and by gene silencing in fibroblast-populated collagen lattice (FPCL) assay, which is used as an in vitro model of Dupuytren's contractures. RESULTS: The three alternative transcripts produced by the EPDR1 gene are all detected in affected Dupuytren's tissue and control unaffected palmar fascia tissue. Dupuytren's tissue also contracts more in the FPCL paradigm. Dicer-substrate RNA-mediated knockdown of EPDR1 results in moderate late stage attenuation of contraction rate in FPCL, implying a role in matrix contraction. CONCLUSION: Our results suggest functional involvement of EPDR1 in the etiology of Dupuytren's Disease.
Authors: Louis Dagneaux; Aaron R Owen; Jacob W Bettencourt; Jonathan D Barlow; Peter C Amadio; Jean P Kocher; Mark E Morrey; Joaquin Sanchez-Sotelo; Daniel J Berry; Andre J van Wijnen; Matthew P Abdel Journal: J Arthroplasty Date: 2020-06-04 Impact factor: 4.757
Authors: Alexandra S Grillos; Jessica M Roach; Amanda M de Mestre; Alastair K Foote; Nicole B Kinglsey; Michael J Mienaltowski; Rebecca R Bellone Journal: Equine Vet J Date: 2022-02-01 Impact factor: 2.692
Authors: Carmel McDougall; Michael J Hammond; Simon C Dailey; Ildiko M L Somorjai; Scott F Cummins; Bernard M Degnan Journal: BMC Evol Biol Date: 2018-12-04 Impact factor: 3.260
Authors: F Gimeno-Valiente; Á L Riffo-Campos; G Ayala; N Tarazona; V Gambardella; F M Rodríguez; M Huerta; C Martínez-Ciarpaglini; J Montón-Bueno; S Roselló; D Roda; A Cervantes; L Franco; G López-Rodas; J Castillo Journal: Sci Rep Date: 2020-02-28 Impact factor: 4.379
Authors: Iina Tuominen; Brie K Fuqua; Calvin Pan; Nicole Renaud; Kevin Wroblewski; Mete Civelek; Kara Clerkin; Ashot Asaryan; Sara G Haroutunian; Joseph Loureiro; Jason Borawski; Guglielmo Roma; Judith Knehr; Walter Carbone; Samuel French; Brian W Parks; Simon T Hui; Margarete Mehrabian; Clara Magyar; Rita M Cantor; Chinweike Ukomadu; Aldons J Lusis; Simon W Beaven Journal: Cell Mol Gastroenterol Hepatol Date: 2020-08-28